Search

Displaying results 5131 - 5140 of 10000 in total
  1. Drug

    Sparteine

    go.drugbank.com/drugs/DB06727
    ApprovedWithdrawn

    Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness … It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents.

  2. Drug

    D-Serine

    go.drugbank.com/drugs/DB03929
    ApprovedInvestigationalWithdrawn

    A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.

    Synonyms: d-Serine
  3. Drug

    Ibudilast

    go.drugbank.com/drugs/DB05266
    Investigational

    Ibudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. … shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS).

  4. Drug

    Docirbrutinib

    go.drugbank.com/drugs/DB21606
    Investigational

    Docirbrutinib has a monoisotopic molecular weight of 578.24 Da. … Docirbrutinib is under investigation in clinical trial NCT05602363 (AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma).

  5. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline. … AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.

  6. Drug

    ROX-888

    go.drugbank.com/drugs/DB05364
    Experimental

    ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.

  7. Drug

    XL019

    go.drugbank.com/drugs/DB05243
    Investigational

    XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.

  8. Drug

    Mizacorat

    go.drugbank.com/drugs/DB21458
    Investigational

    Mizacorat has a monoisotopic molecular weight of 494.21 Da. … Mizacorat is under investigation in clinical trial NCT04556760 (Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes

  9. Drug

    Didesmethylrocaglamide

    go.drugbank.com/drugs/DB15496
    Experimental

    Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus _Aglaia_. … [A186760] While traditionally used for their insecticidal benefits,[A186796] this class of compounds is now being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas

  10. Drug

    ATN-161

    go.drugbank.com/drugs/DB05491
    Investigational

    It inhibits the migration and adhesion of particular integrins on activated endothelial cells that play a critical role in tumor angiogenesis. … Since the expression of alpha(5)beta(1) integrin by cancer cells and the role of this molecule in tumor angiogenesis is similar across a range of different cancers, the therapeutic benefit of ATN-161 is